OSIMERTINIB MESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for osimertinib mesylate and what is the scope of freedom to operate?
Osimertinib mesylate
is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Osimertinib mesylate has one hundred and seventy-six patent family members in forty-three countries.
There are two drug master file entries for osimertinib mesylate. One supplier is listed for this compound. There is one tentative approval for this compound.
Summary for OSIMERTINIB MESYLATE
International Patents: | 176 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 7 |
Patent Applications: | 2,701 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OSIMERTINIB MESYLATE |
DailyMed Link: | OSIMERTINIB MESYLATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OSIMERTINIB MESYLATE
Generic Entry Date for OSIMERTINIB MESYLATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OSIMERTINIB MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
Klus Pharma Inc. | Phase 2 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
Generic filers with tentative approvals for OSIMERTINIB MESYLATE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 80MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 40MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for OSIMERTINIB MESYLATE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inducers Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for OSIMERTINIB MESYLATE
Paragraph IV (Patent) Challenges for OSIMERTINIB MESYLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TAGRISSO | Tablets | osimertinib mesylate | 40 mg and 80 mg | 208065 | 3 | 2019-11-13 |
US Patents and Regulatory Information for OSIMERTINIB MESYLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-002 | Nov 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-002 | Nov 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-002 | Nov 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-002 | Nov 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OSIMERTINIB MESYLATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2843109 | DERIVES DE 2-(ANILINO 2,4,5-SUBSTITUE)PYRIMIDINE UTILISES COMME MODULATEURS DE L'EGFR UTILES POUR LE TRAITEMENT D'UN CANCER (2 -(2,4,5-SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER) | ⤷ Sign Up |
Poland | 3009431 | ⤷ Sign Up | |
European Patent Office | 2736895 | DERUVES DE 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMME MODULATUERS DU EGFR UTILES DANS LE TRAITEMENT DU CANCER (2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER) | ⤷ Sign Up |
Ecuador | SP13013033 | DERIVADOS DE 2-(2,4,5-ANILINO SUSTITUIDO)PIRIMIDINA COMO MODULADORES DE EGFR ÚTILES PARA EL TRATAMIENTO DEL CÁNCER | ⤷ Sign Up |
Japan | 5977779 | ⤷ Sign Up | |
Croatia | P20211682 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OSIMERTINIB MESYLATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1848414 | 300824 | Netherlands | ⤷ Sign Up | PRODUCT NAME: OSIMERTINIB (TAGRISSO); REGISTRATION NO/DATE: EU/1/16/1086 20160204 |
1848414 | C 2016 026 | Romania | ⤷ Sign Up | PRODUCT NAME: OSIMERTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1086; DATE OF NATIONAL AUTHORISATION: 20160202; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1086; DATE OF FIRST AUTHORISATION IN EEA: 20160202 |
1848414 | CA 2016 00033 | Denmark | ⤷ Sign Up | PRODUCT NAME: OSIMERTINIB; REG. NO/DATE: EU/1/16/1086/001-0002 20160204 |
1848414 | 93160 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: OSIMERTINIB (TAGRISSO); FIRST REGISTRATION DATE: 20160204 |
1848414 | 132016000078445 | Italy | ⤷ Sign Up | PRODUCT NAME: OSIMERTINIB(TAGRISSO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1086, 20160204 |
1848414 | 122016000056 | Germany | ⤷ Sign Up | PRODUCT NAME: OSIMERTINIB (TAGRISSO); REGISTRATION NO/DATE: EU/1/16/1086 20160202 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.